The benefits of glofitamab in R/R DLBCL post-CAR-T therapy

The benefits of CAR-T therapy in 2L over 3L in R/R DLBCLПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Choosing the right CAR-T therapy for R/R DLBCLПодробнее

The value of CAR-T cell therapy in R/R DLBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Comparing the efficacy and curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCLПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Who Should Receive CAR-T Cell Therapy for Lymphoma?Подробнее

CD20/CD3 bispecific antibodies in R/R DLBCL: glofitamab and epcoritamabПодробнее

Treatment options for patients with DLBCL who relapse after CAR-T therapyПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

Weighing up the pros and cons of CAR-T therapy and bispecific antibodies in R/R DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

New algorithm for second-line DLBCL: the role of CAR-T therapyПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее